Korean government touts M&A as fastest pharma route into China
This article was originally published in Scrip
Amid the South Korean government's recent drive to encourage pharma firms to shift their focus to overseas markets, an official at the country's state-owned health industry institute has suggested the industry should seek mergers and acquisitions or joint ventures to advance into the rapidly growing Chinese pharma market.
You may also be interested in...
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.